Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer's classical swine fever live vaccine approved
CSF has caused huge economic losses to China's pig farming industry.
Vaccine will play a vital role in eradicating the disease in China.

The first classical swine fever (CSF) live vaccine, jointly developed by Boehringer Ingelheim and Chinese research institutes, has received marketing approval.

The newly-approved Ingelvac CSF MLV is set to provide China's swine industry with breakthrough immunization programmes and support disease solutions. It will also play a vital role in eradicating CSF in the country.

CSF is a highly contagious, lethal disease that has caused huge economic losses to China's pig farming industry. While the outbreak is now effectively controlled by mass vaccination with CSF live vaccine, endemic and sporadic spread remains.

Existing CSF live vaccines can only be stored at -15℃  for 18 months, with strict temperature control requires for transportation, storage and dilution. The new vaccine uses state-of-the-art suspension culture and freeze-drying technologies to ensure stable vaccine production process, and controllable quality. It can be stored at 2-8℃ for 24 months.

In a press release, a Boehringer spokesperson said the vaccine ' marks another milestone for Boehringer Ingelheim’s “in China, for China”, as the company is committed to providing innovative and high-quality swine vaccines for the Chinese swine industry, as well as holistic swine disease solutions to pig farms.'

Ingelvac® CSF MLV will be produced by Boehringer Ingelheim’s Taizhou plant and is expected to be commercialised in early 2021. 

Become a member or log in to add this story to your CPD history

FIVP announces third series of Practice Matters

News Story 1
 The Federation of Independent Veterinary practices (FIVP) has announced a third season of its podcast, Practice Matters.

Hosted by Ian Wolstenholme, series three will focus on the Competition and Markets Authority (CMA) investigation, including a discussion about some of the expected impacts on independent veterinary colleagues.

Episode one launches on 13th January with guests Drs David Reader and Scott Summers, who will draw on their research into the CMA investigation and provide insights into themes such as transparency, pricing and consumer trust.

Ian Wolstenholme said: "In its third series, we will try and hone in on what the changes will mean in reality for independent practices with advice and guidance on implementation and delivery, drawing on the experience of our own team and other experts in the profession. Hope you can join us soon!" 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk